Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: manny t who wrote (464)	2/21/2000 12:51:00 AM
From: JMarcus	Read Replies (2) \| Respond to of 548

>>Did anyone watch CBS Market Watch Weekend?<< I thought that CBS went out of its way to put a negative spin on the artificial blood sector. They referred to the competition among competing products saying "it's bloody out there." They referred to artificial blood as "fake blood." Tauntingly, they challenged: "Right now investors are giddy about anything biotech, but does a good idea necessarily translate into an investment opportunity?" In one breath they would say that the market for these products could reach $1 billion, but in the next breath they'd state that it could be a couple of years before any of the products actually reach the market. They said that analysts are generally cautious about this sector, which they described as "risky," adding that besides the risk of FDA approval, one also faces the risk of market acceptance. The segment did a fair job of explaining the benefits of "fake blood": * unlimited supply * longer shelf life * less risk of infection * can be used on any patient regardless of blood type. Two short excerpts of an interview with ALLP's CEO Duane Roth were shown. In the first shot he was shown stating that part of what is driving this sector is concerns about infectious diseases in donated blood. In the second shot he was stating that this field is attracting attention and that people are asking lots of questions, like what the medical community's acceptance of these new products will be. He appeared very sober, and not the cheerleader I was hoping to see. Four companies were mentioned as competing in this field: BPUR NLFD HMLTO ALLP Nothing was explained about the differences between any of the products being developed by these companies. There were lots of pictures of containers of ALLP's oxygent, which looked like milk, but there was nothing said about how it works. I'm long ALLP, so I was disappointed at the snide and dumbed-down approach CBS elected to take. I won't be a repeat viewer of the program. Marc